Oxidized low-density lipoprotein induces inflammatory responses in cultured human mast cells via toll-like receptor 4

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 842-853

  Meng, Zhe ^a   Yan, Chao ^a   Deng, Qian ^a   Dong, Xin ^a   Duan, Zong Ming ^a   Gao, Deng Feng ^a   Niu, Xiao Lin ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Inflammatory responses; Mast cells; Oxidized low density lipoprotein; Toll like receptor 4

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; OXIDIZED LOW DENSITY LIPOPROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; MESSENGER RNA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPLASM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLAMMATION; MAST CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ATHEROSCLEROTIC PLAQUE; CELL INFILTRATION; GENE SILENCING; NUCLEAR LOCALIZATION SIGNAL; PATHOPHYSIOLOGY; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION;

EID: 84879481236     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350102     Document Type: Article

References (43)

1. Wong BW, Meredith A, Lin D, McManus BM: The biological role of inflammation in atherosclerosis. Can J Cardiol 2012;28:631-641.
2. Insull WJ: The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 2009;122:S3-S14.
3. Libby P: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045-2051.
4. Hansson GK, Hermansson A: The immune system in atherosclerosis. Nat Immunol 2011;12:204-212.
5. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C: Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond) 2011;8:9.
6. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, Witztum JL: The role of innate immunity in atherogenesis. J Lipid Res 2009;50:S388-S393.
7. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, Ballantyne CM: Plasma mcp-1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis risk in communities study. Atherosclerosis 2005;183:301-307. (Pubitemid 41579281)
8. Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, Cuccia M: Inflammation and atherosclerosis: the role of tnf and tnf receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 2007;20:145-154. (Pubitemid 46506886)
9. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-214. (Pubitemid 30064452)
10. Steinberg D, Witztum JL: Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:2311-2316.
11. Fraley AE, Tsimikas S: Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006;17:502-509. (Pubitemid 44372680)
12. Libby P: Inflammation in atherosclerosis. Nature 2002;420:868-874. (Pubitemid 36019640)
13. Huang Y, Hu Y, Mai W, Cai X, Song Y, Wu Y, Dong Y, Huang H, He Z, Li W, Yang Y, Rao S: Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease. Dis Markers 2011;31:295-301.
14. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J: Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 2004;256:413-420. (Pubitemid 39434378)
15. Masuda T, Deng X, Tamai R: Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (mcp-1) and macrophage inflammatory protein-1alpha (mip-1alpha) production in response to toll-like receptor (tlr) 2 and tlr4 agonist via smad3 activation. Int Immunopharmacol 2009;9:1115-1121.
16. Ji Y, Liu J, Wang Z, Li Z: Ppargamma agonist rosiglitazone ameliorates lps-induced inflammation in vascular smooth muscle cells via the tlr4/trif/irf3/ip-10 signaling pathway. Cytokine 2011;55:409-419.
17. Wang W, Deng M, Liu X, Ai W, Tang Q, Hu J: Tlr4 activation induces nontolerant inflammatory response in endothelial cells. Inflammation 2011;34:509-518.
18. Erridge C: Endogenous ligands of tlr2 and tlr4: agonists or assistants? J Leukoc Biol 2010;87:989-999.
19. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized ldl. Circulation 2001;104:3103-3108. (Pubitemid 34014065)
20. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-1161. (Pubitemid 34225814)
21. Bhaskar S, Shalini V, Helen A: Quercetin regulates oxidized ldl induced inflammatory changes in human pbmcs by modulating the tlr-nf-kappab signaling pathway. Immunobiology 2011;216:367-373.
22. Kalesnikoff J, Galli SJ: New developments in mast cell biology. Nat Immunol 2008;9:1215-1223.
23. Libby P, Shi GP: Mast cells as mediators and modulators of atherogenesis. Circulation 2007;115:2471-2473. (Pubitemid 46763219)
24. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, Vogel SN: Tlr4/myd88/pi3k interactions regulate tlr4 signaling. J Leukoc Biol 2009;85:966-977.
25. Baker RG, Hayden MS, Ghosh S: Nf-kappab, inflammation, and metabolic disease. Cell Metab 2011;13:11-22.
26. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D: Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78. (Pubitemid 46718152)
27. Tam SY, Tsai M, Yamaguchi M, Yano K, Butterfield JH, Galli SJ: Expression of functional trka receptor tyrosine kinase in the hmc-1 human mast cell line and in human mast cells. Blood 1997;90:1807-1820. (Pubitemid 27377290)
28. Peluso I, Morabito G, Urban L, Ioannone F, Serafini M: Oxidative stress in atherosclerosis development: the central role of ldl and oxidative burst. Endocr Metab Immune Disord Drug Targets 2012;12:351-360.
29. Kelley JL, Chi DS, Abou-Auda W, Smith JK, Krishnaswamy G: The molecular role of mast cells in atherosclerotic cardiovascular disease. Mol Med Today 2000;6:304-308. (Pubitemid 30619337)
30. Jeziorska M, McCollum C, Woolley DE: Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol 1997;182:115-122. (Pubitemid 27240457)
31. Johnson JL, Jackson CL, Angelini GD, George SJ: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998;18:1707-1715. (Pubitemid 28521059)
32. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, MacFarlane LA, Mallen-St CJ, Shi GP: Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007;13:719-724. (Pubitemid 46889760)
33. Michelsen KS, Doherty TM, Shah PK, Arditi M: Tlr signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004;173:5901-5907. (Pubitemid 39487741)
34. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein e. Proc Natl Acad Sci U S A 2004;101:10679-10684. (Pubitemid 38955802)
35. Geng H, Wang A, Rong G, Zhu B, Deng Y, Chen J, Zhong R: The effects of ox-ldl in human atherosclerosis may be mediated in part via the toll-like receptor 4 pathway. Mol Cell Biochem 2010;342:201-206.
36. Yu M, Kang X, Xue H, Yin H: Toll-like receptor 4 is up-regulated by mtor activation during thp-1 macrophage foam cells formation. Acta Biochim Biophys Sin (Shanghai) 2011;43:940-947.
37. Bzowska M, Nogiec A, Skrzeczynska-Moncznik J, Mickowska B, Guzik K, Pryjma J: Oxidized ldls inhibit tlr-induced il-10 production by monocytes: a new aspect of pathogen-accelerated atherosclerosis. Inflammation 2012;35:1567-1584.
38. Ohlsson BG, Englund MC, Karlsson AL, Knutsen E, Erixon C, Skribeck H, Liu Y, Bondjers G, Wiklund O: Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappab to dna and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. J Clin Invest 1996;98:78-89. (Pubitemid 26243823)
39. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J: Proinflammatory effects of bacterial recombinant human c-reactive protein are caused by contamination with bacterial products, not by c-reactive protein itself. Circ Res 2005;97:e97-e103.
40. Tsan MF: Heat shock proteins and high mobility group box 1 protein lack cytokine function. J Leukoc Biol 2011;89:847-853.
41. Zhong Y, Liu T, Guo Z: Curcumin inhibits ox-ldl-induced mcp-1 expression by suppressing the p38mapk and nf-kappab pathways in rat vascular smooth muscle cells. Inflamm Res 2012;61:61-67.
42. Hong HK, Song CY, Kim BC, Lee HS: Erk contributes to the effects of smad signaling on oxidized ldl-induced pai-1 expression in human mesangial cells. Transl Res 2006;148:171-179. (Pubitemid 44416362)
43. Sun Y, Chen X: Ox-ldl-induced lox-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Fundam Clin Pharmacol 2011;25:572-579.